198 related articles for article (PubMed ID: 30125543)
21. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer.
Park G; Kim TH; Lee HO; Lim JA; Won JK; Min HS; Lee KE; Park DJ; Park YJ; Park WY
Endocr Relat Cancer; 2015 Feb; 22(1):55-63. PubMed ID: 25527510
[TBL] [Abstract][Full Text] [Related]
22. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
23. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract][Full Text] [Related]
24. Detection of an
Lai AZ; Schrock AB; Erlich RL; Ross JS; Miller VA; Yakirevich E; Ali SM; Braiteh F
Oncologist; 2017 Jul; 22(7):774-779. PubMed ID: 28507204
[TBL] [Abstract][Full Text] [Related]
25. Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima.
Iyama K; Matsuse M; Mitsutake N; Rogounovitch T; Saenko V; Suzuki K; Ashizawa M; Ookouchi C; Suzuki S; Mizunuma H; Fukushima T; Suzuki S; Yamashita S
Thyroid; 2017 Jun; 27(6):811-818. PubMed ID: 28351223
[TBL] [Abstract][Full Text] [Related]
26.
Gerthofer V; Scheiter A; Lüke F; Keil F; Utpatel K; Pöhmerer LM; Seitz J; Niessen C; Ignatov A; Dietmaier W; Calvisi DF; Evert M; Ortmann O; Seitz S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568722
[No Abstract] [Full Text] [Related]
27. Case Report of
Lee H; Krishnan V; Wirth LJ; Nucera C; Venturina M; Sadow PM; Mita A; Sacks W
Thyroid; 2022 Dec; 32(12):1580-1585. PubMed ID: 36150036
[TBL] [Abstract][Full Text] [Related]
28. Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer.
Choi Y; Kwon CH; Lee SJ; Park J; Shin JY; Park DY
Br J Cancer; 2018 Jul; 119(2):230-240. PubMed ID: 29955133
[TBL] [Abstract][Full Text] [Related]
29. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.
Knauf JA; Ma X; Smith EP; Zhang L; Mitsutake N; Liao XH; Refetoff S; Nikiforov YE; Fagin JA
Cancer Res; 2005 May; 65(10):4238-45. PubMed ID: 15899815
[TBL] [Abstract][Full Text] [Related]
30. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
33. Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing.
Zhou C; Zeng L; Zhang Y; Yang N
J Thorac Oncol; 2019 Jul; 14(7):e143-e144. PubMed ID: 31235037
[No Abstract] [Full Text] [Related]
34. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
[TBL] [Abstract][Full Text] [Related]
35. Reticular Myxoid Odontogenic Neoplasm with Novel STRN::ALK Fusion: Report of 2 Cases in 3-Year-Old Males.
Rosebush MS; Smith MH; Cordell KG; Callahan N; Zaid W; Gagan J; Bishop JA
Head Neck Pathol; 2024 Mar; 18(1):26. PubMed ID: 38526831
[TBL] [Abstract][Full Text] [Related]
36. Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
Aydemirli MD; van Eendenburg JDH; van Wezel T; Oosting J; Corver WE; Kapiteijn E; Morreau H
Endocr Relat Cancer; 2021 May; 28(6):377-389. PubMed ID: 33878728
[TBL] [Abstract][Full Text] [Related]
37. ALK Rearrangements Characterize 2 Distinct Types of Salivary Gland Carcinomas: Clinicopathologic and Molecular Analysis of 4 Cases and Literature Review.
Agaimy A; Baněčková M; Ihrler S; Mueller SK; Franchi A; Hartmann A; Stoehr R; Skálová A
Am J Surg Pathol; 2021 Sep; 45(9):1166-1178. PubMed ID: 33871952
[TBL] [Abstract][Full Text] [Related]
38. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
39. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
40. Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report.
Zhu L; Ma S; Xia B
Front Oncol; 2022; 12():1009076. PubMed ID: 36439495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]